ACOR
- Acorda Therapeutics, Inc.
()
Overview
Company Summary
Acorda Therapeutics, Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for neurological disorders. Established in 1995 and headquartered in Ardsley, New York, Acorda is dedicated to finding innovative solutions to improve the lives of patients with central nervous system (CNS) disorders.
The company's primary focus is on therapies for people living with multiple sclerosis (MS). Acorda's flagship product is Ampyra (also known as dalfampridine), which is an oral drug approved by the U.S. Food and Drug Administration (FDA) to improve walking in individuals with MS. Ampyra works by enhancing the conduction of nerve signals in the central nervous system, thereby improving mobility.
In addition to Ampyra, Acorda Therapeutics also has several other drug candidates in its pipeline targeting various neurological conditions. These include CVT-301, an inhaled formulation of levodopa in development for the treatment of OFF periods in Parkinson's disease, and Plumiaz (diazepam nasal spray) for the treatment of people with epilepsy who experience cluster seizures.
Furthermore, the company has a robust research and development program focused on novel therapies for conditions like spinal cord injury, post-stroke walking deficits, and Alzheimer's disease.
Acorda Therapeutics aims to improve the lives of patients by addressing unmet needs in the field of neurological disorders through the development of innovative therapies. They work closely with healthcare professionals, patients, and advocacy groups to understand the challenges faced by individuals with CNS disorders and strive to provide effective treatment options to improve their quality of life.